MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
CADL — Candel Therapeutics, Inc. Common Stock
NasdaqCandel Therapeutics, Inc. Common Stock
$10.18
+0.02(+0.20%)
- O
- 10.29
- H
- 10.37
- L
- 10.03
- V
- 877.87K
⏱️ End-of-day dataAs of Oct 2, 2026
Candel Therapeutics, Inc. Common Stock Statistics
Total Valuation
| Market Cap | $843.23M |
| Enterprise Value | $843.09M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | 76.52M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -95,145.98 |
| EV / Sales | n/a |
| EV / EBITDA | -57,000.11 |
| EV / EBIT | -115,539.07 |
| EV / FCF | -45,056.04 |
Financial Position
| Current Ratio | 28.05 |
| Quick Ratio | n/a |
| Debt / Equity | 0.35 |
| Debt / EBITDA | -3.30 |
| Debt / FCF | -2.61 |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | -6.42% |
| Return on Assets (ROA) | -4.39% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-161 |
| Employee Count | 55 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | +88.17% |
| 50-Day Moving Average | $11.44 |
| 200-Day Moving Average | $7.97 |
| Relative Strength Index (RSI) | 44.97 |
| Average Volume (20 Days) | 1,229,593 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -$16.26K |
| Pretax Income | -$8.86K |
| Net Income | -$8.86K |
| EBITDA | -$14.79K |
| EBIT | -$7.30K |
| Loss Per Share | $-0.14 |
Balance Sheet
| Cash & Cash Equivalents | $194.83K |
| Total Debt | $48.82K |
| Net Cash | $146.02K |
| Net Cash Per Share | $0.00 |
| Equity (Book Value) | $138.03K |
| Book Value Per Share | $0.00 |
| Working Capital | $190.70K |
Cash Flow
| Operating Cash Flow | -$5.28K |
| Capital Expenditures | -$-675 |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -$18.71K |
| FCF Per Share | $-0.00 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | 0.00% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |